Professor Jane Armitage
Websites
-
University of Cambridge
Chair of the The Blood Donor Studies Steering Committee
-
University of Cambridge
Chair of RITARAZEM Trial Steering Committee
-
University of Cambridge
Independent Member of AdDIT Trial Steering Committee
-
University of Kelaniya
Clinical Trials Unit Scientific Advisory Board
-
MRC Population Health Research Unit
Researcher
Jane Armitage
FRCP, FFPH, OBE
Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine. In addition, she is Director of Training and Career Development for the Nuffield Department of Population Health.
She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 having qualified in clinical medicine in 1979. She worked in a variety of specialties over several years with particular experience in respiratory medicine, geriatrics and diabetes. Since joining CTSU she has co-ordinated and been chief investigator for a series of large-scale randomised clinical trials in cardiovascular disease including the 20,000 participant MRC/BHF Heart Protection Study, the 12,000 patient SEARCH and 25,000 HPS2-THRIVE study, which are trials of lipid modification in people with or at risk of vascular disease. In addition she is Chief Investigator for the BHF-supported ASCEND trial of aspirin and fish oils involving 15,000 people with diabetes. She collaborates with other epidemiologists and statisticians in NDPH on a variety of genetic and other risk factor studies based on the trial cohorts. She also continues a clinical role in the Lipid Clinic at the Oxford University Hospital NHS Trust and has a particular interest in the safety of statins. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic diseases including osteoporosis.
Key publications
-
Effects of extended-release niacin with laropiprant in high-risk patients.
Journal article
HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212
-
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
Journal article
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494
-
The safety of statins in clinical practice.
Journal article
Armitage J., (2007), Lancet, 370, 1781 - 1790
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Journal article
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Recent publications
-
Evaluation of interventions to prevent vasovagal reactions among whole blood donors: rationale and design of a large cluster randomised trial.
Journal article
McMahon A. et al, (2023), Trials, 24
-
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
Journal article
SAMMONS E. et al, (2023), Contemporary Clinical Trials Communications
-
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Journal article
Harper C. et al, (2023), Heart
-
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Journal article
Zhou J. et al, (2023), Pharmacoeconomics, 41, 547 - 559
-
Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial.
Journal article
Parish S. et al, (2023), Trials, 24